Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders

Blood

Volumn 114, Issue 15, 2009, Pages 3208-3215

  Azakami, Kazuko ^a,b   Sato, Tomoo ^a   Araya, Natsumi ^a   Utsunomiya, Atae ^c   Kubota, Ryuji ^d   Suzuki, Kenshi ^e   Hasegawa, Daisuke ^a   Izumi, Toshihiko ^a   Fujita, Hidetoshi ^a   Aratani, Satoko ^a   Fujii, Ryoji ^a   Yagishita, Naoko ^a   Kamijuku, Hajime ^a   Kanekura, Takuro ^b   Seino, Ken Ichiro ^a   Nishioka, Kusuki ^a   Nakajima, Toshihiro ^a,f,g   Yamano, Yoshihisa ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c Imamura Bun in Hospital   (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

^e JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^f Fukushimura Hospital   (Japan)

^g Misato Marine Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PERFORIN; GALACTOSYLCERAMIDE;

ADULT; ARTICLE; BLOOD; CELL COUNT; CELL LOSS; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOTHERAPY; IN VITRO STUDY; INVARIANT NATURAL KILLER T CELL; MALE; NATURAL KILLER CELL; NATURAL KILLER T CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; T CELL LEUKEMIA; TROPICAL SPASTIC PARAPARESIS; VIRUS LOAD; ADOPTIVE TRANSFER; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED;

ADOPTIVE TRANSFER; ADULT; DENDRITIC CELLS; FEMALE; GALACTOSYLCERAMIDES; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; PARAPARESIS, TROPICAL SPASTIC; VIRAL LOAD;

EID: 70350433785     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-203042     Document Type: Article

References (52)

1. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50(3):481-492. (Pubitemid 8180432)
2. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985;2(8452):407-410. (Pubitemid 15231248)
3. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet. 1986;1(8488):1031-1032. (Pubitemid 16102987)
4. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol. 1998;4(6):586-593. (Pubitemid 29042065)
5. Nagai M, Yamano Y, Brennan MB, Mora CA, Jacobson S. Increased HTLV-I proviral load and preferential expansion of HTLV-I Tax-specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP. Ann Neurol. 2001;50(6):807-812. (Pubitemid 33116143)
6. Yamano Y, Nagai M, Brennan M, et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood. 2002;99(1):88-94.
7. Okayama A, Stuver S, Matsuoka M, et al. Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers. Int J Cancer. 2004;110(4):621-625. (Pubitemid 38658030)
8. Jacobson S. Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. J Infect Dis. 2002;186[suppl 2]:S187-S192. (Pubitemid 35370480)
9. Kannagi M. Immunologic control of human T-cell leukemia virus type I and adult T-cell leukemia. Int J Hematol. 2007;86(2):113-117. (Pubitemid 47425187)
10. Bangham CR. HTLV-1 infection: role of CTL efficiency. Blood. 2008;112(6):2176-2177.
11. Harashima N, Kurihara K, Utsunomiya A, et al. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res. 2004;64(1):391-399. (Pubitemid 38114123)
12. Tomaru U, Yamano Y, Nagai M, et al. Detection of virus-specific T cells and CD8+ T-cell epitopes by acquisition of peptide-HLA-GFP complexes: analysis of T-cell phenotype and function in chronic viral infections. Nat Med. 2003;9(4):469-476. (Pubitemid 36460083)
13. Sabouri AH, Usuku K, Hayashi D, et al. Impaired function of human T-lymphotropic virus type 1 (HTLV-1)-specific CD8+ T cells in HTLV-1-associated neurologic disease. Blood. 2008;112(6):2411-2420.
14. Lanier LL, Chang C, Phillips JH. Human NKRP1A: a disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol. 1994;153(6):2417-2428. (Pubitemid 24278110)
15. Prussin C, Foster B. TCR V alpha 24 and V beta 11 coexpression defines a human NK1 T cell analog containing a unique Th0 subpopulation. J Immunol. 1997;159(12):5862-5870. (Pubitemid 127471520)
16. Porcelli S, Yockey CE, Brenner MB, Balk SP. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8-alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J Exp Med. 1993;178(1):1-16. (Pubitemid 23173239)
17. Dellabona P, Padovan E, Casorati G, Brockhaus M, Lanzavecchia A. An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells. J Exp Med. 1994;180(3):1171- 1176. (Pubitemid 2123074)
18. Exley MA, Hou R, Shaulov A, et al. Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop. Eur J Immunol. 2008;38(6):1756-1766.
19. Montoya CJ, Pollard D, Martinson J, et al. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology. 2007;122(1):1-14. (Pubitemid 47222606)
20. Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med. 2003;198(1):173-181. (Pubitemid 36870197)
21. Kawano T, Nakayama T, Kamada N, et al. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res. 1999;59(20):5102-5105. (Pubitemid 29503967)
22. Nicol A, Nieda M, Koezuka Y, et al. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology. 2000;99(2):229-234. (Pubitemid 30093668)
23. Takahashi T, Nieda M, Koezuka Y, et al. Analysis of human V alpha 24+ CD4+ NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells. J Immunol. 2000;164(9):4458-4464. (Pubitemid 30238040)
24. Metelitsa LS, Naidenko OV, Kant A, et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol. 2001;167(6):3114-3122. (Pubitemid 32852549)
25. Nieda M, Nicol A, Koezuka Y, et al. TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood. 2001;97(7):2067-2074. (Pubitemid 32239088)
26. Ishihara S, Nieda M, Kitayama J, et al. Alpha-glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro. J Immunol. 2000;165(3):1659-1664. (Pubitemid 30604605)
27. Fujii S. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies. Trends Immunol. 2008;29(5):242-249.
28. Raftery MJ, Winau F, Giese T, Kaufmann SH, Schaible UE, Schonrich G. Viral danger signals control CD1d de novo synthesis and NKT cell activation. Eur J Immunol. 2008;38(3):668-679.
29. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol. 2009;9(1):28-38.
30. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984-1987). Br J Haematol. 1991;79(3):428-437.
31. Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458-465.
32. Hermans IF, Silk JD, Gileadi U, et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol. 2003;171(10):5140-5147. (Pubitemid 37432797)
33. Montoya CJ, Jie HB, Al-Harthi L, et al. Activation of plasmacytoid dendritic cells with TLR9 agonists initiates invariant NKT cell-mediated crosstalk with myeloid dendritic cells. J Immunol. 2006;177(2):1028-1039. (Pubitemid 44036605)
34. Jones KS, Petrow-Sadowski C, Huang YK, Bertolette DC, Ruscetti FW. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med. 2008;14(4):429-436.
35. Mostoller K, Norbury CC, Jain P, Wigdahl B. Human T-cell leukemia virus type I Tax induces the expression of dendritic cell markers associated with maturation and activation. J Neurovirol. 2004;10(6):358-371. (Pubitemid 40109623)
36. Chen N, McCarthy C, Drakesmith H, et al. HIV-1 down-regulates the expression of CD1d via Nef. Eur J Immunol. 2006;36(2):278-286. (Pubitemid 43257450)
37. Li D, Xu XN. NKT cells in HIV-1 infection. Cell Res. 2008;18(8):817-822.
38. Yanagisawa K, Seino K, Ishikawa Y, Nozue M, Todoroki T, Fukao K. Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J Immunol. 2002;168(12):6494-6499. (Pubitemid 34620075)
39. Motsinger A, Haas DW, Stanic AK, Van Kaer L, Joyce S, Unutmaz D. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J Exp Med. 2002;195(7):869-879. (Pubitemid 34286758)
40. Sandberg JK, Fast NM, Palacios EH, et al. Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J Virol. 2002;76(15):7528-7534. (Pubitemid 34760975)
41. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science. 1997;278(5343):1626-1629. (Pubitemid 27516282)
42. Seino K, Taniguchi M. Functional roles of NKT cell in the immune system. Front Biosci. 2004;9:2577-2587.
43. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol. 2005;23:877-900. (Pubitemid 40563188)
44. Hishizawa M, Imada K, Kitawaki T, Ueda M, Kadowaki N, Uchiyama T. Depletion and impaired interferon-alpha-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type I-infected individuals. Br J Haematol. 2004;125(5):568-575. (Pubitemid 38747958)
45. Makino M, Wakamatsu S, Shimokubo S, Arima N, Baba M. Production of functionally deficient dendritic cells from HTLV-I-infected monocytes: implications for the dendritic cell defect in adult T cell leukemia. Virology. 2000;274(1):140-148. (Pubitemid 30650689)
46. Richardson JH, Edwards AJ, Cruickshank JK, Rudge P, Dalgleish AG. In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol. 1990;64(11):5682-5687. (Pubitemid 20364571)
47. Kim CH, Butcher EC, Johnston B. Distinct subsets of human Valpha24-invariant NKT cells: cytokine responses and chemokine receptor expression. Trends Immunol. 2002;23(11):516-519. (Pubitemid 35223543)
48. Bricard G, Cesson V, Devevre E, et al. Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol. 2009;182(8):5140-5151.
49. Tupin E, Kinjo Y, Kronenberg M. The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol. 2007;5(6):405-417. (Pubitemid 46780078)
50. Seino K, Taniguchi M. Functionally distinct NKT cell subsets and subtypes. J Exp Med. 2005;202(12):1623-1626. (Pubitemid 41815867)
51. Ishikawa A, Motohashi S, Ishikawa E, et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2005;11(5):1910-1917. (Pubitemid 40471857)
52. Yamaura A, Hotta C, Nakazawa M, Van Kaer L, Minami M. Human invariant Valpha24+ natural killer T cells acquire regulatory functions by interacting with IL-10-treated dendritic cells. Blood. 2008;111(8):4254-4263.